96. クローン病 Crohn disease Clinical trials / Disease details


臨床試験数 : 2,442 薬物数 : 1,278 - (DrugBank : 248) / 標的遺伝子数 : 142 - 標的パスウェイ数 : 209

  
3 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01355614
(ClinicalTrials.gov)
June 201116/5/2011A Phase II Efficacy Study in Fistulizing Crohn's Disease PatientsA Multi-center, Randomized, Double-blind, Active Controlled Study to Assess Efficacy, Safety and Tolerability of the Anti-IL13 Monoclonal Antibody QAX576 in the Treatment of Perianal Fistulas in Patients Suffering From Crohn's DiseaseCrohn's DiseaseDrug: QAX576;Drug: InfliximabNovartis PharmaceuticalsNULLCompleted18 YearsN/AAll10Phase 2Germany;Switzerland
2EUCTR2010-019973-13-DE
(EUCTR)
14/01/201130/09/2010A Phase II Efficacy Study in Fistulizing Crohn's Disease PatientsA multi-center, randomized, double-blind, active controlled study to assess efficacy, safety and tolerability of the anti-IL13 monoclonal antibody QAX576 in the treatment of perianal fistulas in patients suffering from Crohn’s disease Treatment of perianal fistulas in patients suffering from Crohn's Disease.
MedDRA version: 14.0;Level: PT;Classification code 10016717;Term: Fistula;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders
MedDRA version: 14.0;Classification code 10011401;Term: Crohn's disease;System Organ Class: 10017947 - Gastrointestinal disorders
Product Code: QAX576
Trade Name: Remicade
INN or Proposed INN: INFLIXIMAB
Novartis Pharma AGNULLNot RecruitingFemale: yes
Male: yes
23Phase 2Germany;Switzerland
3NCT01316601
(ClinicalTrials.gov)
January 201114/3/2011A Study to Assess Efficacy, Safety and Tolerability of the Anti-IL-13 Monoclonal Antibody QAX576 in the Treatment of Perinanal Fistulas in Patients Suffering From Crohn's DiseaseCrohn's DiseaseDrug: QAX567Gerhard RoglerNovartis PharmaceuticalsCompleted18 YearsN/ABoth3Phase 2Switzerland